FISTENT(Fulvestrant)
Therapeutic class: Estrogen receptor antagonist
Indication: Treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy
250 mg Tablets
250 mg:- A PFS of 250mg- 20°C to 25°C (68°F to 77°F), Shelf Life: 2 Years
- As directed by physician
